Abstract. Previous studies had shown that the exogenous cannabinoids can induce anticonvulsion, which was believed to be mediated through the activation of central cannabinoid Type 1 receptors. Moreover, the endogenous cannabinoid anandamide has shown anticonvulsant properties in the in vitro preparations. The current study used 27 adult Sprague-Dawley rats to investigate the effects of another endogenously occurring cannabinoid called 2-arachidonyl glycerol on epileptiform activity induced by picrotoxin. Extracellular recordings were made from the pyramidal cell layer of the CA1 region of hippocampal slices maintained in an interface type recording chamber. Stimulation was performed by using single pulses. It evoked population spikes of approximately equal amplitude. Using single pulse stimulation, perfusion of 500 nM picrotoxin caused an increase in the amplitude of the first population spike, and caused epilepsy by introducing a second or multiple population spikes. In the presence of picrotoxin, 2-AG reduced the amplitude of the population spikes, thus reducing the epilepsy. The CB 1 receptor antagonist, AM281 (500 nM) had no effect on responses recorded in the presence of picrotoxin, but totally blocked the effect of subsequently perfused 2-AG. The current results showed that 2-AG caused anticonvulsion in the in vitro preparations. The results will open avenues for cannabinoid receptors as possible future therapeutic targets.
Introduction
Although epilepsy is one of the most common neurological conditions, the cellular mechanisms accounting for the neurological abnormalities are not fully understood [1] . The epileptic focus has been shown to contain elevated glutamate levels, and although glutamate antagonists have been investigated as potential antiepileptic drugs, this has as yet proved unsuccessful [2] . In contrast, pharmacological enhancement of GABAergic transmission has proved a powerful mechanism of action for antiepileptic drugs [3] . Therefore, a clear understanding of the pathophysiology of seizure initiation and termination is necessary for our ability to manage seizure disorders and for the potential development of novel antiepileptic agents. Previous research in our laboratory [4] [5] and others [6] [7] have shown that cannabinoid compounds such as WIN55, 212-2 and anandamide are anti-epileptic compounds in both in vitro and in vivo studies. We further demonstrated that the anti-epileptic effect of cannabinoids was mediated through the central cannabinoid Type 1 receptors (CB 1 ) [4] .
To date, two separate cannabinoid receptors (CB 1 and CB 2 ) have been identified. CB 1 was cloned in 1990, whereas CB 2 was cloned in 1993 [8] . CB 1 was found to be present in brain regions such as the hippocampus and is known to mediate the psychoactive effect of cannabinoids, whereas CB 2 receptors were found in the immune system [8] [9] [10] . Following the discovery of cannabinoid receptors, two endogenously occurring agents were discovered in 1992 and 1995 [11] , called arachidonylethanolamide (anandmide) and 2-arachidonylglycerol (2-AG), where there is evidence to suggest that both can serve as neurotransmitters [12] . As our previous studies had shown, an anti-epileptic effect of the cannabinoid CB 1 agonists WIN55, 212-2 and anandamide [4] [5] , the next logical step was to confirm this effect by testing another endogenous cannabinoids (2-AG) in the anti-epileptic scenario, which is the aim of the current study.
Methods
The methods used in the current study are a standard electrophysiological technique that has been used by many previous studies [4] [5] 13] . Twenty-seven young adult Sprague-Dawley rats aged from 4 to 6 weeks were used in the current study. After general anesthesia with halothane, they were decapitated and the brain was removed from the skull and submerged in oxygenated, cold (under 5ºC) artificial cerebrospinal fluid (aCSF). The hippocampus was dissected out and chopped transversely on a McIIwain tissue chopper forming slices 400µm thick. The slices were placed onto moist filter paper in a petri dish and maintained in a well-oxygenated and humidified chamber. After at least one hour, slices were transferred to an interface-type recording chamber which was continuously perfused with aCSF at a rate of 2 ml/minute. The temperature was maintained between 28-30ºC. A pulled bipolar stimulating electrode was used to stimulate the Schaffer collateral commissural fibers, and evoked population spikes were recorded from the cell body layer of the CA1 region of the hippocampus using a glass capillary microelectrode filled with aCSF ( Fig. 1 ). Half-maximal population spikes were then evoked at 30 second intervals until a stable baseline of at least 20 minutes was established. Data was stored and analysed using the LTP program [14] .
2-AG and AM281 were obtained from Tocris (Bristol, UK). Stock solutions of 2-AG were made up in alcohol and stored at 4ºC. When required, they were diluted with aCSF to obtain the required concentration. AM281 (the cannabinoid CB 1 receptor antagonist) was made up as a 10 mM stock solution in dimethyl sulphoxide (DMSO) and diluted in aCSF as required. The convulsant poisonous plant derivative 'picrotoxin' was used to induce convulsion. Picrotoxin has been widely used to induce epilepsy in in vitro preparations [12] . The multiple population spikes recorded after the application of picrotoxin were named PS1, PS2, etc (Fig. 2) . The paired "Student's'" t-test of the INSTAT program was used for statistical analysis. Each slice included in the results came from a different rat. A P value of less than 0.05 was considered statistically significant. 
Results

Picrotoxin Induced Convulsions in the Rat Hippocampal Slice
After recording a steady baseline for at least 20 min, perfusion of picrotoxin (500 nM) for 30 min caused epilepsy by introducing a second population spike (PS2) and increasing the amplitude of both PS1 and PS2. The amplitude of PS2 increased to 157 ± 7% of the control baseline (n=8, Fig. 3 ). 
2-AG is Anticonvulsant in the in vitro Model of Epilepsy
After a steady baseline has been recorded for at least 20 min, picrotoxin (500 nM) was perfused until a second population spike was introduced and had reached a steady baseline. The perfusion of picrotoxin increased the amplitudes of PS1 and PS2. 2-AG (10 µM) was then perfused for 30 min. Perfusion of 2-AG (10 µM) reduced the amplitude of PS1 to 56.4 ± 6% of the picrotoxin baseline. The amplitude of PS2 was reduced to 64 ± 9% of the picrotoxin baseline (n=10, Fig. 4 ). 2-AG therefore showed a strong anticonvulsant effect.
2-AG's Anticonvulsant Effect is Mediated by Cannabinoid's CB 1 Receptor Activation
A pretreatment dose of the cannabinoid CB 1 receptor antagonist, AM281 (500 nM) was used to test if the effect of 2-AG was mediated through the central cannabinoid CB 1 receptors or not. Stable control response was obtained prior to the perfusion of 500 nM picrotoxin. Once a stable second population spike was obtained, the CB 1 receptor antagonist AM281 (500 nM) was perfused for 30 min. This was followed by a perfusion of 2-AG (10 µM) for 30 min. AM281 alone did not affect the amplitude of the PS1 and PS2. After 30 min perfusion of AM281, the amplitude of PS2 was 96 ± 6% of the picrotoxin baseline (i.e. no significant change). AM281 markedly reduced the effect of the subsequently perfused 2-AG (10 µM). The perfusion of 2-AG (10 µM) for 30 min resulted in a very small reduction of the amplitudes of PS1 and PS2 (92 ± 3% and 93 ± 8%, respectively) which were not statistically significant (n=7, p<0.05, Fig. 5 ). 
Discussion
The current study investigated the effects of 2-AG on epileptiform activities induced by picrotoxin. 2-AG showed a potent anticonvulsant action that has been mediated by the activation of the cannabinoid CB 1 receptor.
2-AG is the second putative endogenous ligand for cannabinoid receptors to be identified [15] . It belongs to a class of fatty-acid derivatives of N-arachidonyl-phosphatidylethanolamine [8, 15] . As many previous studies have shown that elevated intracellular calcium accompanies seizure activity [16] [17] , the depolarization and calcium dependent synthesis of endogenous cannabinoids including 2-AG, therefore, suggests that this system could play a significant role in controlling seizure activity [16] [17] . One of the major brain regions involved in epileptogenesis and seizure disorders is the hippocampus [18] , which justify the selection of the hippocampus in the current study.
The most likely cannabinoid receptor involved in the 2-AG anticonvulsant effect is CB 1 receptor [19] . The cannabinoid CB 2 receptor is unlikely to be involved since this receptor is not present in the brain [8, 19] . Moreover, the current study revealed that CB 1 receptor antagonist (AM 281) is selective for the cannabinoid CB 1 receptor, with negligible binding at cannabinoid CB 2 [8] . Thus, the current data strongly suggests the cannabinoid CB1 receptor as the mechanistic site of action controlling the anticonvulsant effects of endocannabinoids. This is in support of previous research using other endocannabinoids to induce anti-convulsion [5, [20] [21] .
In conclusion, the current study is in support of the previous evidence that endocannabinoids play a direct physiological role in modulating seizure activities. In addition, these data further establish the cannabinoid CB 1 receptor and the endogenous cannabinoid system as a potential treatment target for the control of epilepsy. 
